Ethel Ngen

Dr. Ethel Ngen

Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2015 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
SRSangeeta Ray
Sangeeta Ray
ENEthel Ngen
Ethel Ngen
MRMatthew W. Rotz
Matthew W. Rotz
SKSamata Kakkad
Samata Kakkad
ALAla Lisok
Ala Lisok
MPMartin G. Pomper
Martin G. Pomper

10 August 2019 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
SRSangeeta Ray
Sangeeta Ray
VKVivek Kumar
Vivek Kumar
ALAla Lisok
Ala Lisok
JCJian Chen
Jian Chen
IMIl Minn
Il Minn
MPMartin Pomper
Martin Pomper

2 September 2015 in Scientific Reports
Verified
Journal Article
Open access
ENEthel Ngen
Ethel Ngen
LWLee Wang
Lee Wang
YKYoshinori Kato
Yoshinori Kato
BKBalaji Krishnamachary
Balaji Krishnamachary
WZWenlian Zhu
Wenlian Zhu
DADmitri Artemov
Dmitri Artemov
Stem cell therapies are currently being investigated for the repair of brain injuries. Although exogenous stem cell labelling with superparamagnetic iron oxide nanoparticles (SPIONs) prior to transplantation provides a means to noninvasively monitor stem cell transplantation by magnetic resonance imaging (MRI), monitoring cell death is still a challenge. Here, we investigate the feasibility of using an MRI dual-contrast technique to detect cell delivery, cell migration and cell death after stem cell transplantation. Human mesenchymal stem cells were dual labelled with SPIONs and gadolinium-based chelates (GdDTPA). The viability, proliferation rate and differentiation potential of the labelled cells were then evaluated. The feasibility of this MRI technique to distinguish between live and dead cells was next evaluated using MRI phantoms and in vivo using both immune-competent and immune-deficient mice, following the induction of brain injury in the mice. All results were validated with bioluminescence imaging. In live cells, a negative (T2/T2*) MRI contrast predominates and is used to track cell delivery and cell migration. Upon cell death, a diffused positive (T1) MRI contrast is generated in the vicinity of the dead cells and serves as an imaging marker for cell death. Ultimately, this technique could be used to manage stem cell therapies.

1 September 2009 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
ENEthel Ngen
Ethel Ngen
PRPallavi Rajaputra
Pallavi Rajaputra
YYYoungjae You
Youngjae You

Verified
Journal Article
Open access
PDF file
ENEthel Ngen
Ethel Ngen
DADmitri Artemov
Dmitri Artemov
Cell-based therapies are currently being developed for applications in both regenerative medicine and in oncology. Preclinical, translational, and clinical research on cell-based therapies will benefit tremendously from novel imaging approaches that enable the effective monitoring of the delivery, survival, migration, biodistribution, and integration of transplanted cells. Magnetic resonance imaging (MRI) offers several advantages over other imaging modalities for elucidating the fate of transplanted cells both preclinically and clinically. These advantages include the ability to image transplanted cells longitudinally at high spatial resolution without exposure to ionizing radiation, and the possibility to co-register anatomical structures with molecular processes and functional changes. However, since cellular MRI is still in its infancy, it currently faces a number of challenges, which provide avenues for future research and development. In this review, we describe the basic principle of cell-tracking with MRI; explain the different approaches currently used to monitor cell-based therapies; describe currently available MRI contrast generation mechanisms and strategies for monitoring transplanted cells; discuss some of the challenges in tracking transplanted cells; and suggest future research directions.

31 May 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SHSudath Hapuarachchige
Sudath Hapuarachchige
YKYoshinori Kato
Yoshinori Kato
ENEthel Ngen
Ethel Ngen
BSBarbara Smith
Barbara Smith
MDMichael Delannoy
Michael Delannoy
DADmitri Artemov
Dmitri Artemov
This paper reports the damaging effects of magnetic iron-oxide nanoparticles (MNP) on magnetically labeled cancer cells when subjected to oscillating gradients in a strong external magnetic field. Human breast cancer MDA-MB-231 cells were labeled with MNP, placed in the high magnetic field, and subjected to oscillating gradients generated by an imaging gradient system of a 9.4T preclinical MRI system. Changes in cell morphology and a decrease in cell viability were detected in cells treated with oscillating gradients. The cytotoxicity was determined qualitatively and quantitatively by microscopic imaging and cell viability assays. An approximately 26.6% reduction in cell viability was detected in magnetically labeled cells subjected to the combined effect of a static magnetic field and oscillating gradients. No reduction in cell viability was observed in unlabeled cells subjected to gradients, or in MNP-labeled cells in the static magnetic field. As no increase in local temperature was observed, the cell damage was not a result of hyperthermia. Currently, we consider the coherent motion of internalized and aggregated nanoparticles that produce mechanical moments as a potential mechanism of cell destruction. The formation and dynamics of the intracellular aggregates of nanoparticles were visualized by optical and transmission electron microscopy (TEM). The images revealed a rapid formation of elongated MNP aggregates in the cells, which were aligned with the external magnetic field. This strategy provides a new way to eradicate a specific population of MNP-labeled cells, potentially with magnetic resonance imaging guidance using standard MRI equipment, with minimal side effects for the host.